Payment overview · 2025
General Payments
$304.53
9 reported records · 4 companies
Healthcare provider profile · identity verified
Bailey Westerfield Phelps, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HARTFORD, KY · NPI 1962846618
Verified facts
What the public records show
CMS Open Payments records show Bailey Westerfield Phelps, M.D. received $304.53 in general payments during 2025 across 9 reported records.
CVRx, Inc. accounted for 71.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CVRx, Inc. | Unresolved — no canonical attribution shown | $218.53 | 71.8% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.55 | 12.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.93 | 11.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.52 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $304.53 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $218.53 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.55 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 598 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 527 | 104 |
| Omeprazole | Omeprazole | 496 | 111 |
| Montelukast Sodium | Montelukast Sodium | 378 | 78 |
| Losartan Potassium | Losartan Potassium | 362 | 85 |
| Lisinopril | Lisinopril | 316 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 315 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 55 |
| Furosemide | Furosemide | 241 | 42 |
| Famotidine | Famotidine | 227 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 54 |
| Metformin Hcl | Metformin Hcl | 220 | 56 |
| Gabapentin | Gabapentin | 219 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 53 |
| Simvastatin | Simvastatin | 187 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 184 | 40 |
| Metformin Hcl Er | Metformin Hcl | 168 | 38 |
| Sertraline Hcl | Sertraline Hcl | 165 | 39 |
| Ozempic | Semaglutide | 164 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 151 | 36 |
| Buspirone Hcl | Buspirone Hcl | 145 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 145 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 50 |
| Trazodone Hcl | Trazodone Hcl | 132 | 33 |
| Eliquis | Apixaban | 130 | 23 |
| Jardiance | Empagliflozin | 123 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 43 |
| Carvedilol | Carvedilol | 120 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 25 |
| Prednisone | Prednisone | 116 | 66 |
| Atenolol | Atenolol | 112 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 27 |
| Allopurinol | Allopurinol | 108 | 22 |
| Glipizide | Glipizide | 105 | 23 |
| Tramadol Hcl | Tramadol Hcl | 97 | 17 |
| Alendronate Sodium | Alendronate Sodium | 95 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 17 |
| Mounjaro | Tirzepatide | 94 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 19 |
| Donepezil Hcl | Donepezil Hcl | 89 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 23 |
| Potassium Chloride | Potassium Chloride | 87 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 85 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 18 |
| Synthroid | Levothyroxine Sodium | 75 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 16 |
| Xarelto | Rivaroxaban | 73 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 16 |
| Spironolactone | Spironolactone | 70 | 19 |
| Meloxicam | Meloxicam | 65 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 16 |
| Bupropion Xl | Bupropion Hcl | 59 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 11 |
| Trulicity | Dulaglutide | 53 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Mirtazapine | Mirtazapine | 52 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 48 | suppressed |
| Ezetimibe | Ezetimibe | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 16 |
| Lovastatin | Lovastatin | 46 | 11 |
| Colestipol Hcl | Colestipol Hcl | 45 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | suppressed |
| Linzess | Linaclotide | 44 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Ramipril | Ramipril | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 11 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 28 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Estradiol | Estradiol | 32 | 11 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 17 |
| Baclofen | Baclofen | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 12 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Letrozole | Letrozole | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Clozapine | Clozapine | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 14 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Naproxen | Naproxen | 15 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $304.53 · 9 records | CVRx, Inc. | Barostim Neo System, ENDURANT IIS, QULIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error